New anti HCV drugs in the pipeline by Bourlière, Marc
INVITED SPEAKER PRESENTATION Open Access
New anti HCV drugs in the pipeline
Marc Bourlière
From 16
th International Symposium on HIV and Emerging Infectious Diseases
Marseille, France. 24-26 March 2010
Several novel therapeutic approaches are currently in
the pipeline for HCV treatment. They include new tar-
get host immune system as novel interferon, toll-like
receptor agonists, therapeutic vaccines or interleukins,
new target cell replication drug as ribavirin analogues,
cyclophilin inhibitors, alpha glucosidase inhibitors,
dephosphorylationinhibitors of eukaryotic initiation fac-
tors 2alpha, antisense molecule, entry inhibitors and
specifically targeted antiviral therapy (STAT-C) such as
viral enzyme inhibitor ( protease and polymerase). Sev-
eral STAT-C molecules are currently in development
and will soon be at hand and will offer new treatment
opportunities to patients infected with hepatitis C.
Promising results leading to more than 70% of sustained
virological response in genotype 1 naïve patients have
been reported with two proteases inhibitors (telaprevir
and boceprevir) in combination with pegylated inter-
feron and ribavirin that are currently in phase III. These
studies also demonstrated the potential to shorten treat-
ment duration in those with a rapid viral response and
the realistic hope for retreatment success (40 and 75%)
in previous non responders or relapsers to interferon
based therapies. In addition there is early indication that
STAT-C drugs may help to overcome negative host fac-
tors that have historically been associated with poor
response rates (such as ethnicity, insulin resistance, stea-
tosis and cirrhosis). However these trials also emphasize
the limitations of protease inhibitors and viral resistance
data have provided important new lessons for small
molecule drug development. In the near feature, it is
likely that IFN-based therapy plus ribavirin will remain
the backbone of the treatment of chronic hepatitis C.
PEG-IFN and ribavirin are needed in order to prevent
HCV resistance to STAT-C drugs and subsequently
increase SVR. Genotypic and phenotypic resistance tests
will also enter the therapeutic arena. Once several
STAT-C agents without cross resistance become
available, treatment strategies will include a combination
of several drugs with different mechanisms of action
(protease inhibitors and polymerase inhibitors) that
could hopefully results in IFN and/or ribavirin sparing
regimen. The first dual – combination clinical trial with
oral antiviral is still ongoing. Patients receiving this
combination for 14 days had undetectable HCV RNA in
63% of naïve genotype1 patients. This “early success”
has moved IFN-free regimen a step closer to reality for
patients. In the future, there might be combinations of
antivirals having additive potency, lacking cross resis-
tance and with a good safety profile.
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